enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. FS KKR Capital (FSK) Q3 Earnings Preview: What's in the ... - AOL

    www.aol.com/news/fs-kkr-capital-fsk-q3-190107292...

    FS KKR Capital (FSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  3. Ex-dividend date - Wikipedia

    en.wikipedia.org/wiki/Ex-dividend_date

    The ex-date or ex-dividend date represents the date on or after which a security is traded without a previously declared dividend or distribution. [1] The opening price on the ex-dividend date, in comparison to the previous closing price, can be expected to decrease by the amount of the dividend, although this change may be obscured by other ...

  4. Pfizer's Inc. (NYSE:PFE) Dividend is Depending on Vaccine ...

    www.aol.com/news/pfizers-inc-nyse-pfe-dividend...

    The current yield at 3.80% still outperforms the industry, but it mandates further examination as the ex-dividend date is just around the corner. Pfizer's Inc. (NYSE:PFE) Dividend is Depending on ...

  5. FS KKR Capital (FSK) Gains But Lags Market: What You ... - AOL

    www.aol.com/news/fs-kkr-capital-fsk-gains...

    For premium support please call: 800-290-4726 more ways to reach us

  6. COVID-19 vaccination in Italy - Wikipedia

    en.wikipedia.org/wiki/COVID-19_vaccination_in_Italy

    On 10 January 2021, the Campania region in Italy had the highest percentage of administration compared to the doses possessed. It also claimed to have exhausted the stock. [16] [17] On 11 January 2021, 75,075 doses of vaccine were delivered by Pfizer–BioNTech. [12] On 12 January 2021, 47,000 doses of vaccine were delivered by Moderna. [18]

  7. Moderna - Wikipedia

    en.wikipedia.org/wiki/Moderna

    In March 2020, the Food and Drug Administration approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States. [35] [36] In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster. [37]

  8. Pfizer (PFE) Q4 2024 Earnings Call Transcript - AOL

    www.aol.com/pfizer-pfe-q4-2024-earnings...

    Image source: The Motley Fool. Pfizer (NYSE: PFE) Q4 2024 Earnings Call Feb 04, 2025, 10:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...

  9. COVAX-19 - Wikipedia

    en.wikipedia.org/wiki/COVAX-19

    Vaxine began work on a COVID-19 vaccine in January 2020. After developing a vaccine adjuvant the company decided to focus on a "recombinant protein-based vaccine". A phase 1 human trial started in June 2020. The phase 1 trial involved 40 participants, 30 of whom received the vaccine. The remaining ten participants received a saline placebo. [7]